Application segmentation dissects the Yeast Protein Expression Service market by end‑use, clarifying each segment's share of total revenue. Research & Development accounts for roughly 35% of the market, driven by biotech firms seeking rapid prototyping of therapeutic candidates and high‑throughput screening. The Biopharmaceutical Production segment, representing about 30%, reflects large‑scale manufacturing contracts for monoclonal antibodies, vaccines, and complex biologics where yeast offers cost‑effective glycosylation control. Industrial Enzyme Production contributes 20%, as manufacturers of detergents, food additives, and biofuels outsource expression to achieve high yields of robust enzymes. Finally, Academic Research holds 15%, encompassing university labs and government institutes that require customized expression vectors and scale‑up support. Collectively, these application categories form the backbone of the Yeast Protein Expression Service segmentation, each influencing investment decisions, pricing strategies, and service portfolio development across the market.